X4 Pharmaceuticals Executive Compensation (FY25)
XFOR · Executive and director compensation, fiscal 2024 to 2025
The paid brief on X4 Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of September 7, 2026Latest filing (8-K): May 12, 2026
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
$1,500Get the executive brief
94 figures on this page: 90 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
This company is not required to report a chief executive pay ratio.
More on X4 Pharmaceuticals
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Paula Ragan: $2,145,041 → $2,640,569 (23.1% higher)
Frequently asked questions
Answers drawn from the data on this page.
What was X4 Pharmaceuticals' say-on-pay result?
The say-on-pay proposal drew 92.9% support at the meeting held May 11, 2026 for fiscal 2025.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Paula Ragan Former President and Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Adam Craig Executive Chairman | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
John Volpone President and Chief Operating Officer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
David Kirske Chief Financial Officer, Treasurer and Corporate Secretary | ◇ | ◇ | — | ◇ | ◇ | — | ◇ | ◇ |
Paula Ragan Former President and Chief Executive Officer Departed during or after this year | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| David Kirske | Option | ◇ | — | ◇ | 8/13/2035 |
| Option | ◇ | — | ◇ | 8/11/2035 | |
| Option | ◇ | — | ◇ | 8/11/2035 | |
| John Volpone | Option | ◇ | — | ◇ | 8/13/2035 |
| Option | ◇ | — | ◇ | 8/11/2035 | |
| Option | ◇ | — | ◇ | 8/11/2035 | |
| Adam Craig | Option | ◇ | — | ◇ | 8/13/2035 |
| Option | ◇ | — | ◇ | 8/11/2035 | |
| Option | ◇ | — | ◇ | 8/11/2035 |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Michael S. Wyzga Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Gary J. Bridger | ◇ | ◇ | — | — | — | — | ◇ |
Gary J. Bridger, Ph.D | ◇ | ◇ | — | — | — | — | ◇ |
Murray W. Stewart, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Françoise De Craecker | ◇ | ◇ | — | — | — | — | ◇ |
David McGirr, M.B.A | ◇ | ◇ | — | — | — | — | ◇ |
Keith Woods | ◇ | ◇ | — | — | — | — | ◇ |
William E. Aliski, MPA | ◇ | — | — | — | — | — | ◇ |
Alison Lawton | ◇ | — | — | — | — | — | ◇ |
Adam R. Craig, M.D., Ph.D., M.B.A served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | May 11, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | June 9, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 10, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | June 13, 2023 | = | ◇ | ◇ | ◇ |
What this page does not include
Everything above is a fact X4 Pharmaceuticals disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
94 figures on this page: 90 cited to the filing that reported them, 4 calculated from figures it prints.
90 cited to the filing
4 calculated from the filing
Documents cited
- 0001501697-26-000047Item 5.07. Submission of Matters to a Vote of Security Holders.
- 0001501697-26-000031Director Compensation Table · Outstanding Equity Awards at Fiscal Year-End · Summary Compensation Table
- 0001628280-25-030743Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-24-027680Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001628280-23-022266Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “X4 Pharmaceuticals executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/XFOR (accessed 2026).
Short form: data: Velarion
The paid brief for X4 Pharmaceuticals
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
5 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about X4 Pharmaceuticals and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}